In line, a trend towards higher expressions of COL6A1, F2R, and ITGA2 was seen in the blast phase CML compared to samples at initial diagnosis (Fig. S10C). This evidence concerns the gene COL6A1 and chronic myelogenous leukemia, BCR-ABL1 positive.